Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Inclusion criteria: * Healthy Adult males or females between 18 and 55 years of age, inclusive. * Female subjects must be of non-childbearing potential * Body weight \> 50 kg (110 pounds) and body mass index (BMI) 19 and 31 where: * Subjects with QTc \< 450 msec at screening (or QTc \< 480 msec for subjects with Bundle Branch Block). * A signed and dated written informed consent prior to admission to the study. * The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restriction Exclusion criteria: * Systolic blood pressure \< 100 mmHg or 150 mmHg and/or diastolic blood pressure = 100 mmHg at screening. * History of significant cardiac arrhythmias * Active peptic ulcer disease (PUD) and/or history of PUD within 1 year. * A serum uric acid concentration 8mg/dL * Screening test positive for H. Pylori using the non-radioactive breath test * History of gout and/or hyperuricemia * History of Gilbert's syndrome * A serum creatinine concentration above the normal reference range * History of kidney stones * PT and/or aPTT above the reference range * History of recurrent indigestion, stomach upset or diarrhea * Liver function tests (LFTs) or creatinine phosphokinase (CPK) 1.5X ULN * Screening stool test positive for occult blood * Screening peripheral blood smear with abnormal RBCs * CBC, MCV, and/or reticulocyte count corrected for haemoglobin level above the reference range at screening * Reduced G6PD activity * Serum haptoglobin outside the reference range at screening * Total serum LDH \> 1.25% above the ULN at screening * Positive HIV, Hepatitis B or Hepatitis C at screening * The subject has a positive pre-study urine drug/ serum alcohol screen. * History of alcohol consumption exceeding, on average, 7 drinks/week for women or 14 drinks/week for men within 6 months of the first dose of study medication or a positive alcohol test at screening * History of use of tobacco or nicotine containing products within 6 months of screening or a positive urine cotinine screen * Use of prescription (including hormone replacement therapy) or non-prescription drugs and vitamins within 7 days or 5 half-lives prior to administration of study medication. An exception is acetaminophen which is allowed at doses of 2g/day. * Use of dietary/herbal supplements within 14 days prior to treatment with study medication * Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to dosing. * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. * Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period. * Unwillingness of male subjects to use a condom/spermicide * Pregnant or nursing women. * History of flushing (\>1 episode annually). * Fasting blood glucose 110 mg/dl and/or history of type I or type II DM * History of intra-ocular pathology * History of recurrent gum bleeding * History of bleeding haemorrhoids